Table 2.

Evaluation of the response of 1A9-PTX22 tumor xenografts to paclitaxel and SU6668 treatments

TreatmentDose (mg/kg)Schedule (× no. treatments)n*%T/C (day)T − C
P1SU6668100Q1 × 10941 (22)9
PTX6Q1 × 10974 (22)2
PTX + SU66686Q1 × 10934 (22)13
100Q1 × 10
P2SU6668100Q1 × 10840 (20)4
PTX20Q4 × 3781 (17)1
PTX + SU666820Q4 × 3730 (20)12
100Q1 × 10
  • NOTE: In two separate protocols (P1 and P2), 1A9-PTX22 was transplanted s.c. in nude mice and treatments began when tumors reached ∼300 mg. P1 shows the response of tumors where mice received daily treatments of SU6668 (100 mg/kg orally, Q1 × 10), paclitaxel (6 mg/kg i.v., Q1 × 10), or the combination. P2 shows the response of xenografts to SU6668 (100 mg/kg orally, Q1 × 10), paclitaxel (20 mg/kg i.v., Q4 × 3), or the combination. No significant body weight loss was observed in the treated groups. PTX, paclitaxel.

  • * n = number of mice evaluated.

  • %T/C ≤ 40%.

  • P < 0.01.